StemCells Inc Share Price Nasdaq
Stocks
US85857R2040
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 11-05 | Microbot Medical Adds Canadian Patent to IP Portfolio | MT |
| 10-27 | Microbot Medical Inc. Announces ELMNT IR as First Office-Based Lab Customer for LIBERTY Endovascular Robotic System | CI |
| Market Cap | 74.55M 66.87M 61.11M 55.78M 105M 7.01B 108M 737M 294M 3.74B 280M 274M 11.8B | P/E 2026 * |
-3.64x | P/E 2027 * | -3.47x |
|---|---|---|---|---|---|
| Enterprise Value | 74.55M 66.87M 61.11M 55.78M 105M 7.01B 108M 737M 294M 3.74B 280M 274M 11.8B | EV / Sales 2026 * |
58.5x | EV / Sales 2027 * | 12.2x |
| Free-Float |
100% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: StemCells Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Harel Gadot
CEO | Chief Executive Officer | 54 | 01/08/1988 |
Rachel Vaknin
DFI | Director of Finance/CFO | 48 | 31/03/2022 |
Michal Ahuvia
COO | Chief Operating Officer | - | 20/01/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Harel Gadot
CHM | Chairman | 54 | 31/12/2012 |
Scott Burell
BRD | Director/Board Member | 61 | 27/11/2016 |
Martin Madden
BRD | Director/Board Member | 66 | 05/02/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.83% | +3.51% | +55.00% | +63.79% | 65.94B | |
| -1.34% | +2.98% | +25.08% | +100.18% | 56.53B | |
| +0.02% | +1.07% | +11.72% | +75.63% | 56.88B | |
| +5.09% | +9.89% | +27.19% | +105.85% | 46.49B | |
| +2.62% | +1.68% | +29.16% | +35.86% | 44.8B | |
| +8.24% | +0.51% | +215.16% | +794.74% | 41.59B | |
| -1.86% | +10.13% | +28.14% | +55.48% | 35.35B | |
| -2.97% | -9.84% | +90.91% | +73.49% | 33.29B | |
| -2.18% | +7.06% | +40.97% | -3.11% | 24.92B | |
| Average | +0.31% | +3.25% | +58.15% | +144.66% | 45.09B | |
| Weighted average by Cap. | +0.21% | +3.40% | +54.89% | +143.13% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.27M 1.14M 1.04M 953K 1.8M 120M 1.85M 12.59M 5.02M 63.9M 4.78M 4.68M 202M | 6.09M 5.46M 4.99M 4.55M 8.58M 572M 8.85M 60.15M 23.98M 305M 22.85M 22.36M 964M |
| Net income | -20.67M -18.54M -16.95M -15.47M -29.15M -1.94B -30.06M -204M -81.45M -1.04B -77.6M -75.94M -3.27B | -21.82M -19.57M -17.88M -16.32M -30.76M -2.05B -31.73M -216M -85.95M -1.09B -81.89M -80.13M -3.45B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
